检索

标题
作者
New approaches in the treatment of aggressive subtypes of endometrial cancer and the prognostic role of HER2 status of the tumor: A systematic review
Saevets V., Kuzmin N., Shamanova A.
Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case
Radyukova I., Rats N.
Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case
Kolyadina I., Ganshina I., Zhukova L., Abdullaev A., Andreeva Y., Danzanova T., Sinyukova G., Komov D., Kozlov N., Filonenko D., Gordeeva O., Lubennikova E.
Following in the footsteps of ASCO-2025: TOP studies that will change the treatment strategy of advanced HR+ and HER2+ breast cancer. A review
Kolyadina I., Poddubnaya I.
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.
High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
Seryakov A., Ovchinnikova L., Zabelin M., Yakubov T., Sidorov D., Ovchinnikov M.
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K., Sukhova M., Kolyago E., Filonenko D., Zhukova L.
Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
Evdokimov V., Bloshchinenko A., Abolmasov A., Vilensky A., Laskov M.
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L., Ganshina I., Khatkova E., Tikhomirova T., Kondratyeva O.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013
Frank G., Poddubnaya I., Yagudina R., Borisov D., Koroleva N.
Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii
Frank G., Poddubnaya I., Yagudina R., Borisov D.
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D., Kolyadina I., Poddubnaya I., Ganshina I., Khokhlova S., Kоmetova V., Rodionov V.
Immunogistokhimicheskoe opredelenie ekspressii HER2/neu pri rake molochnoy zhelezy (po dannym Smolenskogo oblastnogo onkologicheskogo klinicheskogo dispansera)
Shisterova O., Golik E.
The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan
Berdimyradova M., Khadjiev S., Khommadova D., Polatova G., Kakajanova A., Batyrov C., Penayev D., Agayeva B., Annaberdiyeva G.
1 - 14 的 14 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回(例如,隐含AND)
  • 使用OR结合多个检索词,便于查找含有这些检索词的文章,例如education OR research
  • 使用括号来创建更复杂的查询; 例如:archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如: "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如:online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).